News | CT Angiography (CTA) | June 25, 2018

Post-Mortem CT Angiography Illuminates Causes of Death

PMCTA detects 90 percent of incidental findings in examination of 500 bodies, while autopsy only finds 61 percent

Post-Mortem CT Angiography Illuminates Causes of Death

June 25, 2018 — Computed tomography (CT) angiography is a useful adjunct to autopsy that is likely to increase the quality of post-mortem diagnosis, according to a study appearing online in the journal Radiology. Researchers said the findings could have important implications for criminal investigations and hospital quality control efforts.

High-quality post-mortem investigations are vital for a number of reasons; most notably, as evidence in criminal investigations for which the body represents the main proof of a crime; and as a quality control measure for surgical interventions and medical treatment at hospitals.

Modern imaging techniques like CT and magnetic resonance imaging (MRI) are often used in forensic pathology. However, post-mortem CT is limited by relatively low soft tissue contrast and poor visualization of the vascular system. A technique known as post-mortem CT angiography (PMCTA) was developed to address those limitations by introducing contrast agent into the body.

“The idea of the PMCTA is to simulate a post-mortem circulation by establishing a post-mortem perfusion of the vascular system,” said study lead author Silke Grabherr, M.D., Ph.D., from the University Center of Legal Medicine Lausanne-Geneva in Lausanne, Switzerland. “Therefore, the heart is ‘replaced’ by a perfusion device, similar to the heart-lung machine that replaces the heart during heart surgery.”

To assess the performance of PMCTA, Grabherr and colleagues at nine centers in Europe performed conventional autopsies on 500 human bodies that had undergone PMCTA. All CT images were read by an experienced team, including one forensic pathologist and one radiologist who were blinded to the autopsy findings.

Autopsy was performed on the day of the PMCTA, or the following day, in all cases. After examination of 500 bodies, a total of 18,654 findings were recorded.

PMCTA performed surprisingly well compared to conventional autopsy. Out of 18,654 total findings, PMCTA found 90 percent, compared with 61 percent for autopsies. PMCTA missed only 10 percent of forensically essential findings, while autopsy missed 23 percent.

“This method could — in many cases — be an alternative to invasive autopsy if such an opening of the body is not possible,” Grabherr said. “This offers new investigation possibilities, for example, in countries where a conventional autopsy is not accepted or in cases where family members can refuse it.”

PMCTA was significantly superior to autopsy at identifying skeletal and vascular lesions, or areas of damage in the bones and blood vessels. PMCTA identified 96 percent of skeletal lesions and 94 percent of vascular lesions, compared with 65 percent for autopsy. These lesions can provide important information in post-mortem examinations, Grabherr said.

“The combination of bone lesions and vascular lesions is especially seen in cases of traumatic death, such as falls from height, traffic accidents, ballistic trauma, and sharp trauma in homicides and suicides,” she said. “This means that PMCTA is an excellent choice to investigate such cases and can be used combined with or even independently of conventional autopsy for investigating in these cases.”

In the future, the research group plans to study the combination of post-mortem angiography with MRI in order to increase the sensitivity of findings related to organs like the brain and liver.

For more information: www.pubs.rsna.org/journal/radiology

 

Reference

Grabherr S., Heinemann A., Vogel H., et al, “Postmortem CT Angiography Compared with Autopsy: A Forensic Multicenter Study.” Radiology, May 1, 2018. https://doi.org/10.1148/radiol.2018170559


Related Content

Feature | CT Angiography (CTA) | Kyle Hardner

Advances in coronary CT angiography (CCTA) over the past two decades have helped cardiologists detect heart disease in ...

Home February 06, 2026
Home
News | CT Angiography (CTA)

Jan. 9, 2026 — Effective January 1, 2026, Elucid's Plaque-IQ coronary plaque analysis has received a new Category I ...

Home January 09, 2026
Home
News | CT Angiography (CTA)

Dec. 11, 2025 — Heartflow, Inc., a provider of AI technology for coronary artery disease (CAD), recently announced two ...

Home December 11, 2025
Home
News | CT Angiography (CTA)

Dec. 8, 2025 — In November, The Lancet published an international expert consensus review, “Contemporary, non-invasive ...

Home December 11, 2025
Home
News | CT Angiography (CTA)

Oct. 27, 2025 — At the annual Transcatheter Cardiovascular Therapeutics (TCT 2025) meeting in San Francisco, Royal ...

Home October 30, 2025
Home
News | CT Angiography (CTA)

Oct., 2025 — Elucid, an AI medical technology company focused on providing physicians with a more precise view of ...

Home October 29, 2025
Home
News | CT Angiography (CTA)

Oct. 22, 2025 — Qure has announced its latest (510) K clearance from the US Food and Drug Administration (FDA). The ...

Home October 23, 2025
Home
News | CT Angiography (CTA)

Sept. 2, 2025 — GE HealthCare recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for ...

Home September 09, 2025
Home
News | CT Angiography (CTA)

Aug. 11, 2025 — Elucid announced that United Healthcare has updated its cardiac imaging guidelines to align with recent ...

Home August 11, 2025
Home
News | CT Angiography (CTA)

April 30, 2025 – Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, has launched Viz ...

Home May 02, 2025
Home
Subscribe Now